Medilink member Mast have recently announced the launch of a new addition to the Mastdiscs® stock cartridge range – Ceftolozane/tazobatam 30/10 (C/T40C), is now available!
Merck (MSD) has launched the new intravenous antibiotic Zerbaxa® (Ceftolozane/tazobactam) in the UK for the treatment of complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections in nosocominal environments. It was approved for use in the USA from December 2014.
Ceftolozane/tazobactam provides an alternative to carbapenems for the treatment of Extended Spectrum β-lactamase (ESβL) producing organisms. Overuse of carbapenems has been known to contribute to the global dissemination of resistance.
Professor David Livermore, Professor in Medical Microbiology at University of East Anglia, says: “Ceftolozane/tazobactam is very important because it’s a new antibiotic that treats Gram-negative infections, where a lot of resistance problems are now accumulating. Its activity against pseudomonas is especially important.
“It overcomes both the major mechanisms – efflux and inactivation – that often compromise other cephalosporins against this difficult species. As always, there’s more to be done, more clinical trials are needed in further settings – particularly those where you find most of the difficult Pseudomonas strains.”
Additionally, EUCAST released clinical breakpoints in January for antibiotic susceptibility test discs ceftolozane/tazobatam 30/10 (C/T40C). These are conveniently available from Mast in a stock cartridge format, each pack containing 5 x 50 discs and compatible with Mast’s new DiscMaster 4 dispenser (MDD64). Contact Mast now for more information on firstname.lastname@example.org.